Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flonotinib Malate vs Ruxolitinib in Intermediate/High-Risk Myelofibrosis (Phase III)
CTR20255078Phase 3Active
- Sponsor
- Zeling Biopharma
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of flonotinib in myelofibrosis (MF), primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), post-essential thrombocythemia myelofibrosis (PET-MF), sponsored by Zeling Biopharma. Started Feb 2026; status: active.
02
Drugs
flonotinib
03
Conditions
myelofibrosis (MF)primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)post-essential thrombocythemia myelofibrosis (PET-MF)
Beyond the preview
Go deeper on CTR20255078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20255078.